Results Earnings Call for Q2FY23 of Divi's Laboratories
Conference Call with Divi's Laboratories Management and Analysts on Q2FY23 Performance and Outlook. Listen to the full earnings transcript.07-11-2022
07-11-2022
DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Further to our intimation letter dated October 28, 2022, we hereby inform that the audio recording of the earnings conference call for the quarter and half year ended September 30, 2022, held on November 07, 2022 at 14.00 Hrs IST has been uploaded on the Company's website at the following weblink: https://www.divislabs.com/wp-content/uploads/2022/11/Earnings-Call-Audio-Q2FY23_07.11.2022.mp307-11-2022
Q2FY23 Quarterly Result Announced for Divi's Laboratories Ltd.
Divi's Laboratories announced Q2FY23 results: Divi's Laboratories Limited (Divi's/the Company) has earned a consolidated total income of Rs 1,935 crore for Q2FY23 as against a consolidated total income of Rs 2,007 crore in the corresponding Q2FY22 Profit before tax (PBT) for Q2FY23 amounted to Rs 615 crore as against a PBT of Rs 760 crore for the corresponding Q2FY22 Profit after tax (PAT) for Q2FY23 amounted to Rs 494 crore as against a PAT of Rs 606 crore for Q2FY22 For Q2FY23, we have a forex gain of Rs 31 crore as against a loss of Rs 7 crore during Q2FY22. For H1FY23, the company earned a consolidated total income of Rs 4,278 crore as against a consolidated total income of Rs 3,996 crore during H1FY22 PAT for H1FY23 to Rs 1,196 crore as against Rs 1,164 crore for the previous H1FY22. For H1FY23, we had a forex gain of Rs 87 crore as against a gain of Rs 13 crore during the corresponding H1FY22. Result PDF07-11-2022
Two Saurabh Mukherjea portfolio stocks - Divis Labs, Tarsons Products - fall sharply after Q2 results
Divi's Labs' net profit for the second quarter (Q2 FY23) fell about 18%07-11-2022
DIVI'S LABORATORIES LTD. - 532488 - Board Meeting Outcome for Outcome Of Board Meeting Held On 07.11.2022 - Unaudited Financial Results (Standalone And Consolidated) For The Quarter And Half Year Ended September 30, 2022
Further to our intimation dated October 28, 2022, we would like to inform that the Board of Directors of the Company at its meeting held on November 07, 2022 has, inter alia, approved the Unaudited Financial Results for the quarter and half year ended September 30, 2022. In terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith the following: 1. Unaudited standalone financial results for the quarter and half year ended September 30, 2022 along with Limited Review Report of the Statutory Auditors thereon. 2. Unaudited consolidated financial results for quarter and half year ended September 30, 2022 along with Limited Review Report of the Statutory Auditors thereon. 3. Press Release on the said Financial Results of the Company. The Board meeting commenced at 11.30 Hrs and concluded at 12.40 Hrs.07-11-2022
DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we are enclosing herewith the schedule of Earnings conference call Q2FY23 to be held on November 07, 2022.28-10-2022
DIVI'S LABORATORIES LTD. - 532488 - Board Meeting Intimation for Considering And Approving The Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2022
DIVI''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/11/2022 ,inter alia, to consider and approve the standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2022. As intimated earlier, the Trading Window for dealing in securities of the Company has been closed from October 01, 2022 till 48 hours after the declaration of financial results as per the Company's Code of Conduct for Prevention of Insider Trading pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015.28-10-2022
DIVI'S LABORATORIES LTD. - 532488 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, we herewith submit certificate for the quarter ended September 30, 2022 received from M/s. KFin Technologies Limited, Registrar & Share Transfer Agent of the Company.12-10-2022
DIVI'S LABORATORIES LTD. - 532488 - Closure of Trading Window
Intimation of Closure of Trading Window from October 01, 202229-09-2022
Buy Divis Laboratories; target of Rs 4450: Sharekhan
Sharekhan is bullish on Divis Laboratories has recommended buy rating on the stock with a target price of Rs 4450 in its research report dated August 26, 2022.27-08-2022